Chugai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

33.62

P/S

9.85

EPS

197.79

Div Yield, %

1.20%

Shrs. gr., 5y

0.01%

Rev. gr., 5y

13.90%

Revenues

1.11t

-11.79%

Net income

325.47b

-13.08%

CFO

409.93b

+67.92%

Dividend

Dec 27, 202441 JPY/sh

Earnings

Jan 30, 2025

Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

URL

https://www.chugai-pharm.co.jp/

IPO date

Mar 03, 1956

Employees

7,771

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	1,111,367,000 -11.79%	1,259,946,000 26.02%	999,759,000 27.04%
Cost of revenue	700,754,000	726,637,000	577,862,000
Unusual Expense (Income)
NOPBT	410,613,000	533,309,000	421,897,000
NOPBT Margin	36.95%	42.33%	42.20%
Operating Taxes	118,349,000	156,737,000	116,390,000
Tax Rate	28.82%	29.39%	27.59%
NOPAT	292,264,000	376,572,000	305,507,000
Net income	325,472,000 -13.08%	374,429,000 23.58%	302,995,000 41.10%
Dividends	(131,594,000)	(138,220,000)	(98,644,000)
Dividend yield	1.50%	2.49%	1.61%
Proceeds from repurchase of equity	212,000	236,000	314,000
BB yield	0.00%	0.00%	-0.01%
Debt
Debt current		6,434,000	6,550,000
Long-term debt	6,480,000	7,245,000	9,000,000
Deferred revenue	378,000	430,000	490,000
Other long-term liabilities	12,585,000	14,555,000	15,641,000
Net debt	(733,756,000)	(210,327,000)	(254,596,000)
Cash flow
Cash from operating activities	409,925,000	244,112,000	279,626,000
CAPEX	(71,948,000)	(71,239,000)	(72,866,000)
Cash from investing activities	(37,290,000)	(145,994,000)	(118,927,000)
Cash from financing activities	(139,331,000)	(145,641,000)	(107,408,000)
FCF	294,323,000	196,713,000	206,936,000
Balance
Cash	738,982,000	503,107,000	471,970,000
Long term investments	1,254,000	(279,101,000)	(201,824,000)
Excess cash	684,667,650	161,008,700	220,158,050
Stockholders' equity	1,556,225,000	1,355,582,000	1,119,795,000
Invested Capital	953,875,350	1,185,824,300	903,737,950
ROIC	27.32%	36.04%	36.77%
ROCE	24.97%	39.39%	37.29%
EV
Common stock shares outstanding	1,645,499	1,645,338	1,645,229
Price	5,342.00 58.61%	3,368.00 -9.83%	3,735.00 -32.13%
Market cap	8,790,255,567 58.63%	5,541,498,155 -9.82%	6,144,931,185 -32.12%
EV	8,056,499,567	5,331,171,155	5,890,335,185
EBITDA	442,353,000	564,743,000	452,765,000
EV/EBITDA	18.21	9.44	13.01
Interest		61,000	48,000
Interest/NOPBT		0.01%	0.01%